CN1696289A - Protein of tuberculosis in use for diagnosing tuberculosis - Google Patents
Protein of tuberculosis in use for diagnosing tuberculosis Download PDFInfo
- Publication number
- CN1696289A CN1696289A CN 200410044568 CN200410044568A CN1696289A CN 1696289 A CN1696289 A CN 1696289A CN 200410044568 CN200410044568 CN 200410044568 CN 200410044568 A CN200410044568 A CN 200410044568A CN 1696289 A CN1696289 A CN 1696289A
- Authority
- CN
- China
- Prior art keywords
- tuberculosis
- albumen
- present
- mycobacterium tuberculosis
- proteic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 75
- 108090000623 proteins and genes Proteins 0.000 title abstract description 34
- 102000004169 proteins and genes Human genes 0.000 title abstract description 26
- 239000013612 plasmid Substances 0.000 claims abstract description 18
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 68
- 238000012360 testing method Methods 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 33
- 238000003745 diagnosis Methods 0.000 claims description 32
- 238000012544 monitoring process Methods 0.000 claims description 23
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 238000011835 investigation Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 8
- 238000005215 recombination Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 abstract description 10
- 102000040430 polynucleotide Human genes 0.000 abstract description 10
- 239000002157 polynucleotide Substances 0.000 abstract description 10
- 241000186359 Mycobacterium Species 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 42
- 102100028626 4-hydroxyphenylpyruvate dioxygenase Human genes 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 14
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 14
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 12
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 239000013566 allergen Substances 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000193830 Bacillus <bacterium> Species 0.000 description 9
- 241000700199 Cavia porcellus Species 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 230000008521 reorganization Effects 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000004153 renaturation Methods 0.000 description 8
- 238000013016 damping Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 208000009146 rhinoscleroma Diseases 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 5
- 230000000405 serological effect Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 108020005038 Terminator Codon Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005325 percolation Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 3
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 230000037029 cross reaction Effects 0.000 description 3
- 238000003391 densitometric scan Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- -1 thalline polysaccharide Chemical class 0.000 description 3
- 229960002109 tuberculosis vaccine Drugs 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 102220369447 c.1352G>A Human genes 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 206010025226 lymphangitis Diseases 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- WDCYWAQPCXBPJA-UHFFFAOYSA-N 1,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC([N+]([O-])=O)=C1 WDCYWAQPCXBPJA-UHFFFAOYSA-N 0.000 description 1
- VXPSQDAMFATNNG-UHFFFAOYSA-N 3-[2-(2,5-dioxopyrrol-3-yl)phenyl]pyrrole-2,5-dione Chemical group O=C1NC(=O)C(C=2C(=CC=CC=2)C=2C(NC(=O)C=2)=O)=C1 VXPSQDAMFATNNG-UHFFFAOYSA-N 0.000 description 1
- UHBAPGWWRFVTFS-UHFFFAOYSA-N 4,4'-dipyridyl disulfide Chemical compound C=1C=NC=CC=1SSC1=CC=NC=C1 UHBAPGWWRFVTFS-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 206010027259 Meningitis tuberculous Diseases 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000022971 Tuberculous meningitis Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010047124 Vasculitis necrotising Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 102220369446 c.1274G>A Human genes 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000001223 meningeal tuberculosis Diseases 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 108060006184 phycobiliprotein Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A tuberculosis mycobacterium protein used for diagnosing tuberculosis and epidemiologic survey and monitor of tuberculosis, the polynucleotide for coding it, the hybrid plasmid and procaryotic host cell containing said polynucleotide, and the process for preparing said protein are disclosed.
Description
Technical field
The present invention relates to a kind of Mycobacterium tuberculosis albumen that utilizes genetically engineered preparation, and this albumen is in diagnosis of tuberculosis, tuberculosis epidemiology investigation and Application in Monitoring with it is as the application of antigen composition in vaccine.
Background technology
Mycobacterium tuberculosis is pathogenic bacterium lungy, and about three million peoples in the annual whole world suffer from the tuberculosis that tubercule bacillus causes.China is that 22 tuberculosis height are born one of country in the world, and patient's number occupies the second place of the world, is only second to India.In recent years, number of the infected lungy is in rising trend again in China.
Tuberculosis is a kind of respiratory infectious disease, therefore, to this disease early stage, accurately diagnosis is a key of effectively controlling this disease wide-scale distribution.
In the twenties in 20th century, the foreign study person the thickening filtration thing of the tubercule bacillus cracked soluble product of growing in the liquid nutrient medium has been made allergen for skin test (ot, OT).Seiber in 1934 sets up ammonium sulfate salting-out process and has prepared PPD.Nineteen eighty-two, China began to develop PPD, its basic preparation method is: the logical substratum of will reviving is cultivated 8-10 week culture for 37 ℃, 100 ℃ of 60min deactivation after-filtration are removed thalline, precipitate with the final concentration 2% Tricholroacetic Acid method of saltouing then, the purifying protein derivative, this protein derivatives is PPD[kingdom and controls, middle national defence consumptive disease magazine, 1991].OT and PPD all can cause the DTH reaction of mycobacterium sensitization body, are widely used in the tuberculosis tentative diagnosis, tuberculosis epidemiology investigation and monitoring.But, since among OT and the PPD except that the albumen derivative, also comprise the tubercule bacillus meta-bolites, some compositions in thalline polysaccharide, nucleic acid, lipid material and the substratum etc. usually cause non-specific cross-reaction and other side reactions.U.S. Konstantin points out that in report PPD antigen and nearly all mycobacterium have common antigen, exists cross reaction widely [Konstantin L, et al., Infection and Immunity, 1998]; Huang Jian report, in 1184 crowds' epidemiology survey, the skin abnormality reaction appears in injection site, as blister appears, downright bad to account for 1.7%[yellow strong, middle national defence consumptive disease magazine, 1994]; Reports such as Liu Yuandong, blister wherein appears in PPD skin test strong positive 266 people, downright bad number is 132 people, accounts for 49.6%[Liu Yuan east etc., middle national defence consumptive disease magazine, 2000]; Among report such as Wu Lanzhen 89 routine tuberculosis diseases (pulmonary tuberculosis, the outer tuberculosis of the lung) patient, blister appears in the PPD skin test, and necrosis and reaction range surpass the above person of 20mm and account for 34.7%[Wu Lan treasure etc., middle national defence consumptive disease magazine, 1991].In addition, also have the only a few patient systemic anaphylaxis reaction behind the PPD skin test, to occur, as allergy necrotizing vasculitis, anaphylactoid purpura, lymphangitis, anaphylactic shock etc.
In view of PPD exists above-mentioned toxic side effects and poor specificity problem, in recent years, that the researchist can replace in searching, more special, many good tries have been carried out in safer allergen aspect, in numerous researchs, Mycobacterium tuberculosis 38KDa albumen receives much attention.
Mycobacterium tuberculosis 38KDa albumen is the main immunogen of Mycobacterium tuberculosis, has stronger immunocompetence.National scholar's joint studies such as Britain such as Wilkinson, Denmark, Italy, India, Germany, in report in 1997, do the test of cavy DTH allergen with 38KDa albumen, its effect is better than 17KDa, 19KDa, 24KDa and 32KDa albumen, and its effectiveness is similar substantially to PPD.This 38KDa albumen brings out by mycobacterium sensitized guinea pig in Mycobacterium tuberculosis, BCG (bacille Calmette-Guerin vaccine) and the born of the same parents and produces DTH, and do not take place or the only extremely slight reaction [Wilkinson et al, Journal of Clinical Microbiology 1997] of generation with bird mycobacterium, mycobacterium kansasii, scrofula mycobacterium.Although this 38KDa albumen has allergen characteristic preferably, the problem that exists is that the synthetic 38KDa albumen of Mycobacterium tuberculosis is few, only accounts for the thousandth of total protein.Because it is low and need cultivate and operate poisonous bacterial classification in a large number to obtain the 38KDa protein yield by Mycobacterium tuberculosis, there is the danger that infects the people, therefore, the research worker has dropped into a large amount of experimental studies, produces reorganization 38KDa albumen by genetic engineering technique fermentation intestinal bacteria.At present, though produce 38KDa albumen its output is increased greatly by genetically engineered, for example, M.Singh etc. are by recombination bacillus coli K-12 bacterial strain CAG629[pMS9-2] prepared reorganization Ag38 albumen, the Recombinant Protein Expression amount has reached 10% of total cell protein, but such expression amount can not satisfy the needs of clinical diagnosis of tuberculosis and tuberculosis epidemiology investigation far away, has influenced the practical application of this albumen in the tuberculosis field.
At present the utmost point need find a kind of can mass production, have good specificity again, and a safer Mycobacterium tuberculosis allergen, overcome people and thirst for the existing problem of diagnosis of tuberculosis and screening aspect that solves for a long time.
The present invention is by big quantity research, found a kind of Nucleotide of particular sequence, with importing prokaryotic host cell behind the nucleic acid construct recombinant expression vector with this nucleotide sequence, as expression in escherichia coli, the expression of recombinant proteins amount is multiplied, reaches and account for 36% of total bacterioprotein.And the albumen after the expression confirms that by animal experiment and clinical trial it has good allergen to render a service and specificity highly, and side reaction is minimum.
Summary of the invention
The invention summary
The invention discloses the proteic nucleotide sequence shown in sequence 2 of a kind of Mycobacterium tuberculosis of encoding, utilize this nucleotide sequence to prepare the proteic method of Mycobacterium tuberculosis, and by the Mycobacterium tuberculosis albumen of this method preparation.
Mycobacterium tuberculosis albumen of the present invention is by the expression of nucleic acid of nucleotide sequence shown in the sequence 2.Expressed proteic aminoacid sequence is shown in sequence 3.
The nucleotide sequence of the present invention shown in sequence 2 can insert in the carrier that is adapted at expressing in the prokaryotic host cell and be built into expression vector, thereby expresses in prokaryotic host cell.Preferred procaryotic cell expression carrier is PET9d, PET22b (+) or PET15b plasmid; Preferred prokaryotic host cell is intestinal bacteria, more preferably BL21 (DE3) or HMS174 (DE3).
The present invention utilizes nucleotide sequence shown in the sequence 2 to prepare Mycobacterium tuberculosis albumen by gene engineering method and can realize as follows:
1) obtains to have the polynucleotide sequence shown in the sequence 2;
2) this polynucleotide sequence is imported plasmid, preferred PET9d, PET22b (+) or PET15b plasmid;
3) this plasmid is imported prokaryotic host cell, preferred, e. coli host cell is more preferably among BL21 (DE3) or the HMS174 (DE3);
4) under the condition that helps described polynucleotide sequence expression, cultivate described host cell; With
5) recombinant protein that recovery, purifying and renaturation are expressed.
The invention still further relates to and comprise proteic composition of Mycobacterium tuberculosis of the present invention and test kit.Described composition can be used as diagnosis of tuberculosis and tuberculosis epidemiology investigation and monitoring reagent, is used for investigation, screening and the monitoring of clinical diagnosis lungy and tuberculosis epidemiology.
Described albumen or composition also can be prepared into reagent box for tuberculate diagnosis or tuberculosis epidemiology investigation screening reagent box, are advantageously used in investigation, screening and the monitoring of clinical diagnosis lungy and tuberculosis epidemiology.
The present invention relates to investigation of a kind of new diagnosis of tuberculosis method and tuberculosis epidemiology and monitoring method, this method comprises that utilization comprises proteic reagent of Mycobacterium tuberculosis of the present invention or test kit, by tuerculoderma, or serological test comes the diagnosis of tuberculosis patient, or filters out the tuberculosis suspected patient.Therefore, the invention still further relates to the reagent or the test kit that comprise the proteic tuberculosis skin diagnosis of Mycobacterium tuberculosis of the present invention or epidemiology survey and monitoring, and the reagent or the test kit that comprise the proteic tuberculosis serological diagnosis of Mycobacterium tuberculosis of the present invention or epidemiology survey and monitoring.
Mycobacterium tuberculosis albumen of the present invention confirms to have good immunogen by animal and clinical trial and renders a service, and have high specificity, the little characteristics of side effect as the tubercule bacillus allergen.Therefore, it may occur to persons skilled in the art that Mycobacterium tuberculosis albumen of the present invention can be used to prepare the Mycobacterium tuberculosis vaccine, as subunit vaccine etc.Equally, the nucleotide sequence shown in sequence 2 disclosed in this invention also can be used to prepare dna vaccination, in order to prevention tuberculosis.Therefore, the invention still further relates to the Mycobacterium tuberculosis vaccine that comprises Mycobacterium tuberculosis albumen of the present invention or nucleic acid.
Detailed Description Of The Invention
The invention discloses the proteic nucleotide sequence shown in sequence 2 of a kind of Mycobacterium tuberculosis of encoding, utilize this nucleotide sequence to prepare the proteic method of Mycobacterium tuberculosis, the Mycobacterium tuberculosis albumen that comprises aminoacid sequence shown in the sequence 3 by this method preparation, and comprise this proteic composition and test kit, their application in diagnosis of tuberculosis and tuberculosis epidemiology investigation and monitoring are also disclosed simultaneously.In addition, Mycobacterium tuberculosis albumen of the present invention and nucleic acid of the present invention also can be used for the preparation of Mycobacterium tuberculosis vaccine.
One embodiment of the invention relate to the proteic nucleotide sequence shown in sequence 2 of a kind of Mycobacterium tuberculosis of encoding.Base be numbered conventional 5 ' to 3 ' (initiation codon of translation chain is to the termination codon order) in proper order.
Nucleotide sequence shown in the sequence 2 can be by the method preparation of this area routine, preferably according to the Pab gene order, nucleotide sequence shown in sequence 1 (being numbered conventional 5 ' to 3 ' in proper order of base), the synthetic one couple of PCR primers of design, the primer of sequence increases shown in the preferred sequence 4 and 5, and amplified production is carried out following sudden change: make its disappearance 5 ' end 1-72 bit base 1.; 2. 76-78 bit base TCG is sported TCT; 3. making termination codon is TAA.
The change of polynucleotide sequence structure influences for example secondary structure of nucleic acid higher structure, thereby influences the expression level of this nucleic acid in host cell.The present invention finds that have as mentioned above the nucleic acid molecule of structure can improve the expression productive rate greatly with suitable carrier and host cell expression the time.
One embodiment of the invention relate to the nucleotide sequence of application shown in sequence 2 and prepare the proteic method of Mycobacterium tuberculosis.According to conventional methods, can with contain code book invention Mycobacterium tuberculosis proteic shown in sequence 2 cDNA or the DNA nucleic acid molecule of nucleotide sequence be connected in the expression vector, then by the ordinary method transformant.Conversion is meant as the outer composition of karyomit(e) or DNA is imported biological so that this DNA can duplicate through chromosomal integration.According to used host cell, use the standard technique that is suitable for this cell to transform.Cohen, institute of NAS newspaper, 69:2110 (1972) and Mandel etc., the molecular biology magazine, the calcium processing of the described employing calcium chloride of 53:154 (1970) generally is used for protokaryon or other contains the cell of a large amount of cell walls obstacles.
Usually, preferred prokaryotic organism are used for the initial clone of dna sequence dna and are used for vector construction of the present invention.For example, intestinal bacteria, genus bacillus such as subtilis and such as the various bacteriums of other bacterium of enterobacteriaceaes such as Salmonella typhimurium or serratia marcescens and Rhodopseudomonas.
In general, contain with the plasmid vector of matched replicon of prokaryotic host cell and regulating and controlling sequence and can both be used in combination with described host.But the proteic dna sequence dna of optimized encoding the present invention is inserted into PET9d, PET22b (+) or PET15b (+) carrier forms recombinant expression vector.The heterozygosis plasmid that code book is invented proteic nucleic acid and PET9d, PET22b (+) or PET15b (+) formation has the stability of height, helps the proteic expression of the object of the invention.
The promotor of Mycobacterium tuberculosis can not be discerned by the e. coli rna polysaccharase, the T7 phage rna polymerase can only be discerned the T7 phage promoter, so select T7 phage promoter should select the to encode host bacterium of T7 phage rna polymerase could realize expression.Contain (DE3) lysogen in theory, and the host bacterium that does not produce the T7 phage rna polymerase before expressing protein all can be selected, for example, HMS174 (DE3), JM109 (DE3), BL21 (DE3) all can efficiently express the object of the invention albumen, but preferred HMS174 (DE3) and BL21 (DE3), these two kinds of proteic output of host cell expression the object of the invention are higher, and its fast growth, help enhancing productivity.
In a preferred embodiment of the invention, as shown in Figure 1, preparation contains the expression construct of the nucleic acid molecule and the PET9d plasmid of polynucleotide sequence shown in the sequence 2, and this construct is transformed BL21 (DE3), after 4-5 hour, collects thalline through the IPTG inducing culture.The target protein expression amount is through the quantitative assay of gel densitometric scan, and the result accounts for the proteic 36%-40% of whole cell, and the gained target protein detects through mass spectroscopy, and molecular weight is 35.8KDa.
Can adopt the conventional resulting albumen of purification process purifying, and make its renaturation.Known purification process comprises, for example the absorption and desorption, ultracentrifugation, gel-filtration, affinity chromatography or the specificity purification process that carry out of ion-exchanger.Albumen of the present invention behind the purifying can be with comprising, for example, dithiothreitol (DTT) or 3-mercaptoethanol are in interior conventional reduction agent renaturation.
One embodiment of the invention relate to the Mycobacterium tuberculosis albumen with method for preparing, purifying, renaturation, and this albumen has aminoacid sequence shown in the sequence 3.
One embodiment of the invention relate to and comprise proteic composition of Mycobacterium tuberculosis of the present invention and test kit.Described composition or test kit can be prepared into diagnosis of tuberculosis and tuberculosis epidemiology investigation and monitoring reagent or kit form.
One embodiment of the invention relate to and comprise the proteic diagnosis of tuberculosis of Mycobacterium tuberculosis of the present invention and tuberculosis epidemiology investigation and monitoring reagent.In this product, albumen of the present invention can dry powdered form exist, and is diluted to desired concn before use; Also can certain density solution form exist.Comprising the investigation of proteic diagnosis of tuberculosis of Mycobacterium tuberculosis of the present invention and tuberculosis epidemiology can comprise a container and be positioned at label or package insert this vessel surface or relevant with this container with monitoring reagent.Proper container has bottle, bottle, syringe etc.Container can be made by various materials such as glass or plastics.This container can include and detect the proteic composition of the present invention lungy, and has aseptic access port (for example this container can be the bottle that has stopper that can be by the intradermal injection needle penetration).Described label or described using method and the description of use that comprises the proteic composition of Mycobacterium tuberculosis of the present invention of package insert explanation.In addition, this product also can further comprise second container, wherein can contain pharmaceutically useful buffer reagent, for example the sterilized water of injection (BWFI), phosphate-buffered salt, Ringer ' solution and glucose solution.Also can comprise other material that satisfies user's needs, as other damping fluid, thinner, filter, syringe needle and syringe.
Another embodiment of the present invention relates to the test kit that contains the proteic diagnosis of tuberculosis of Mycobacterium tuberculosis of the present invention and epidemiology survey, screening and monitoring, be used for clinically easily and fast and diagnosis of tuberculosis accurately, and, more apparent its advantage of this test kit in carrying out large-scale tuberculosis epidemiology investigation and monitoring.
" test kit " described herein is meant and utilizes albumen of the present invention to finish that tuberculosis detects and reagent set that assembly is made.This test kit is used for diagnosis of tuberculosis, or is used for epidemiological survey lungy and monitoring.In this test kit, comprise a container, this container contains Mycobacterium tuberculosis albumen of the present invention.Mycobacterium tuberculosis albumen of the present invention can be any easily, suitable packaging means packs.For example, if it is a freeze-dried preparation, the ampoule or the phial of band elastic plug can be used as container usually, prepare certain density protein solution of the present invention so that can inject liquid through elastic plug.The ampoule most convenient of ampoule of nonelastic removable lid (as sealed glass) or band elastic plug is used for the proteic injectable forms of Mycobacterium tuberculosis of the present invention.Test kit of the present invention also can comprise other a plurality of containers, wherein can contain to detect used standard substance antibody, the enzyme of antibody or process mark, substrate or damping fluid etc. respectively.In this test kit, comprise that also label and package insert are in order to provide the operation instruction of test kit.Also can comprise other material that meets user's needs, as microtiter plate or the like.
At the test kit that is used for the tuberculosis serological auxiliary detection, Mycobacterium tuberculosis albumen of the present invention also can be through mark.Specifically can use marks such as enzyme, fluorescent substance, luminophore, radioactive substance, metallo-chelate.Preferred mark enzyme for example, peroxidase, alkaline phosphatase, beta-D-galactosidase, malate dehydrogenase (malic acid dehydrogenase), staphylococcal nuclease, δ-5-steroid isomerase, α-Gan Youlinsuantuoqingmei, Triosephosphate isomerase, horseradish peroxidase, asparaginase, glucose oxidase, rnase, urease, catalase, glucose-6-phosphate dehydrogenase (G6PD), glucoamylase, and acetylcholinesterase etc.Preferred fluorescent substance has fluorescein isothiocyanate, phycobiliprotein, rhodamine, phycoerythrin, Phycocyanins, C-, allophycocyanin, and Phthalyldicarboxaldehyde.Preferred luminophore has different luminol,3-aminophthalic acid cyclic hydrazide, lucigenin, luminol,3-aminophthalic acid cyclic hydrazide, aromatic series acridinium ester, imidazoles, acridinium salt and modification type ester thereof, luciferin, luciferase, and aequorin.Preferred radioactive substance has
125I,
127I,
131I,
14C,
3H,
32P,
35S etc.Preferred metallics has Radioactive colloidal gold etc.
With above-mentioned marker bonded method be known.Specifically can use direct and indirect labelling method.Direct labelling method commonly used is, with albumen of the present invention and marker by a kind of linking agent with chemical covalent bonds.Linking agent has N, N '-adjacent phenylene dimaleimide, 4-(N-maleimide aminomethyl) cyclohexylenedinitrilotetraacetic acid N-succinimide ester, 6-maleimide lpsilon N-succinimide ester, 4,4 '-dithio pyridine, and other known linking agent.The example of indirect labelling method has, albumen of the present invention is combined with lower molecular weight haptens such as vitamin H, dinitrobenzene, pyridoxal or fluorescamine, and with albumen of the present invention with haptenic in conjunction with the counterpart indirect labelling.The recognition ligand that avidin and streptavidin can be used as vitamin H uses.
When marker was enzyme, its substrate and developer can be used for measuring its activity.When using peroxidase, with H
2O
2As substrate solution, and with 2,2 '-azine-two-[3-ethyl benzo thiazole phenanthroline sulfonic acid] ammonium salt (ABTS), 5-aminosalicylic acid, O-Phenylene Diamine, the amino antipyrine or 3 of 4-, 3 ', 5,5 '-tetramethyl benzidines etc. are as developer.When using alkaline phosphatase, available ortho-nitrophenyl phosphoric acid, p-nitrophenyl phosphoric acid etc. are as substrate.When using beta-D-galactosidase, can use fluorescein-two-(β-D-gala pyranoside), 4-methyl umbrella shape base (umbelliferyl)-β-D-gala pyranoside etc. as substrate.
One embodiment of the invention relate to using and comprise the proteic reagent of Mycobacterium tuberculosis of the present invention or test kit to individuality, for example tuberculosis suspected patient, the epidemic-stricken area crowd individuality that maybe might infect tubercule bacillus detects, with auxiliary diagnosis lungy or filter out suspicious patient.
In one embodiment, the present invention relates to a kind of new diagnosis of tuberculosis or epidemiology survey monitoring method, described diagnosis or epidemiology survey and monitoring comprise proteic reagent of Mycobacterium tuberculosis of the present invention or test kit by application, adopt conventional serological method to realize, for example, can use the tuberculosis mycobacteria antibodies that comprises in proteic reagent of Mycobacterium tuberculosis of the present invention or the body fluid such as test kit detection serum, cerebrospinal fluid.The method that detects the tuberculosis mycobacteria antibodies has indirect test, as Mycobacterium tuberculosis proteantigen of the present invention is adsorbed in solid phase carrier, add serum to be checked then, exist if any corresponding antibodies, then on carrier, form antigen-antibody complex with antigen, the washing back adds enzyme mark anti-antibody or colloid gold label anti-antibody, the colour developing observations.Described indirect test method is ELISA method, spot enzyme immunity percolation method, spot gold-marking immunity percolation process etc. for example.Perhaps, serology detects can use sandwich assay, for example, makes sample to be checked and the albumen test of the present invention that is bonded to the activated protein of the present invention and the mark of insoluble carrier, detects the antibody amount in the sandwich complex of this reaction generation.Perhaps also available competition experiments is carried out the detection of tuberculosis mycobacteria antibodies, for example, make tuberculosis mycobacteria antibodies and the tuberculosis mycobacteria antibodies in the sample and the protein competition reaction of the present invention of mark, according to determining the amount of the tuberculosis mycobacteria antibodies in the sample with the amount of the tuberculosis mycobacteria antibodies of the mark of albumen test of the present invention.Tiring of tuberculosis mycobacteria antibodies is higher than contrast 1-4 doubly in the sample, and preferred 2-3 times, more preferably 2 times, clinically tuberculosis there is the auxiliary diagnosis meaning, aspect the tuberculosis epidemiology investigation meaning of monitoring is being arranged.
Any biological sample as body fluid such as blood plasma, serum, blood, urine, tissue juice or cerebrospinal fluid, as long as they contain the tuberculosis mycobacteria antibodies, with regard to available albumen of the present invention, comprises this proteic composition or test kit and detects.
In one embodiment, the present invention relates to a kind of new diagnosis of tuberculosis or epidemiology survey monitoring method, described diagnosis or epidemiology survey and monitoring comprise proteic reagent of Mycobacterium tuberculosis of the present invention or test kit by application, adopt for example tuberculosis intradermal vaccination tuerculoderma commonly used to carry out auxiliary diagnosis lungy, or carry out epidemiology survey lungy and monitoring.For example, albumen of the present invention can for example pass through, available Motouw method, and sterilization 1ml disposable syringe is drawn 0.1ml Mycobacterium tuberculosis albumen of the present invention in the 1/3 place intradermal injection of left forearm palmar, and seeing has skin mound proof to inject successfully.Measured horizontal stroke, the vertical footpath (mm) of injection site blush or subcutaneous scleroma in back 24 hours in injection.Average horizontal stroke, the vertical diameter 〉=5mm of injection site blush (or scleroma) are positive, and mean diameter<5mm or reactionless (with 0 expression) are negative.In epidemiology survey lungy, behind the healthy population intradermal vaccination tuerculoderma reagent, to the skin test reactions positive particularly the healthy population of strong positive be the main crowd that tuberculosis prophylaxis need be monitored.
Detect and skin detection is used in testing comprises proteic all reagent of Mycobacterium tuberculosis of the present invention or test kit all comprises within the scope of the invention at above-mentioned tuberculosis serological.
Description of drawings
Fig. 1 shows the recombinant plasmid cleavage map.The linear plasmid DNA of the segmental goal gene of the as seen about 1.1kb of expression plasmid double digestion and about 4.5kb; The single endonuclease digestion expression plasmid only sees and is about the 5.6kb fragment that the dna sequence dna of proteins encoded contains the proteic gene of pre-expression in restriction enzyme site and carrier successful connection accurately in the recombinant plasmid, and the foreign gene that inserts size is consistent with theory.
Fig. 2-A-Fig. 2-B is dna sequence dna figure.This figure show dna sequence meets fully with design, and the mutational site sequence is correct, and is in full accord with genomic dna sequence with the genome complementation part.
Fig. 3 shows recombinant bacterial strain SDS-polyacrylamide gel electrophoresis figure.This figure shows engineering bacteria express recombinant protein under the IPTG inductive condition, and engineering bacteria is induced express recombinant protein hardly without IPTG.
Fig. 4 shows engineering bacterium expression expression of recombinant proteins amount.IPTG induces the scanning of engineering bacteria whole cell proteins gel electrophoresis to show that target protein accounts for 36% of total tropina, and peak 14 is the object of the invention recombinant proteins among the figure.
Fig. 5 is the purification result of recombinant protein of the present invention.Solubilization of inclusion bodies liquid obtains the higher recombinant protein of purity through twice anion column chromatography.During chromatography purification, the albumen applied sample amount is 10 μ g.Purifying is a band after the SDS-polyacrylamide gel electrophoresis is identified.
Fig. 6 is the proteic amino acid composition analysis figure of the present invention, and framework is accurate when inserting the gene coded protein in the carrier, and frameshit does not take place, and amino acid is formed with theoretical consistent, shows that Mycobacterium tuberculosis protein nucleic acid molecule of the present invention obtains to express in intestinal bacteria.
Fig. 7 is N end sequencer map.The N terminal sequence shows that the methionine(Met) of ATG coding is fallen N terminal amino acid sequence entirely accurate by the enzyme enzymolysis in the intestinal bacteria; Framework accurately is not shifted when further showing gene coded protein.
Specific embodiments
Hereinafter, reference example of the present invention is specifically addressed, but these embodiment are not construed as limiting the invention.
Embodiment 1: the proteic preparation of Mycobacterium tuberculosis of the present invention
According to the Pab gene order, by round pcr the Pab gene to be suddenlyd change, author designed has been synthesized one couple of PCR primers.Long 37 bases of upstream primer a1, shown in sequence 4,5 ' end has designed protection base and NCOI restriction enzyme site (containing codon ATG), long 34 bases of downstream primer a2, shown in sequence 5,5 ' end design BamHI restriction enzyme site and termination codon TAA.With Mycobacterium tuberculosis H37Rv genomic dna is template, archaeal dna polymerase round pcr by high-fidelity obtains code book and invents proteic polynucleotide (wherein 5 ' the end base sequence is ATGGGCTCT-(sequence 1) or ATGGGCTCA-(sequence 2), and wherein the most last base is suddenlyd change by former bases G.The pcr amplification product of this primer is through 1.2% agarose gel electrophoresis, and ultraviolet detection presents the specific amplified band, is about 1050bp, adheres to specification.The coding triplet TCG that the PCR product has removed N end coding 24 amino acid whose coding triplets (72 bases), original encoding the 26th amino acids sports TCT, termination codon is TAA.
Polynucleotide are cut with the BamHI enzyme through NCOI with expression vector after separate through 1.0% agarose gel electrophoresis, and cutting contains the agar block of DNA band, and press DNA fast purifying test kit specification sheets recovery DNA.Polynucleotide that reclaim and PET9d plasmid expression vector are at T
4Connect into reorganization heterozygosis plasmid under the dna ligase effect, reorganization heterozygosis plasmid transformed competence colibacillus e. coli jm109, by selecting the screening of recombination bacillus coli bacterium colony and identifying the intestinal bacteria bacillus JM109 that contains reorganization heterozygosis plasmid, require the single endonuclease digestion and the double digestion collection of illustrative plates of reorganization heterozygosis plasmid to meet Fig. 1.The goal gene that inserts in the reorganization heterozygosis plasmid automatically checks order through DNA and proves that sequence and design meet fully.The correct reorganization heterozygosis plasmid of target gene sequences transforms expressive host bacterium BL21 (DE3), when this recombination bacillus coli is cultured to optical density(OD) and is 0.6-0.8, adds 0.4mmol/L IPTG inducing culture, induces 4-5 hour, collects thalline.Under this inducing culture condition, the target protein expression amount accounts for the proteic 36%-40% of whole cell through the gel densitometric scan.Albumen of the present invention has been realized efficiently expressing by the change of nucleotide sequence and the selection of carrier and host cell.
Embodiment 2: the proteic purifying of Mycobacterium tuberculosis of the present invention, renaturation and evaluation
Thalline adds lysis buffer (the 1g bacterium adds the 3ml lysis buffer) suspension thalline.The ultrasonication bacterium, power 200W, ultrasonic 20 seconds, gap 20 seconds, ultrasonic 80 times altogether; Centrifugal 15 minutes of 4 ℃, 12000rpm are abandoned supernatant, and precipitation is washed 2-3 time with containing 1%Triton-X100 respectively.20mmol/LTris.Cl/8M urea (pH8.0) dissolving inclusion body, 4 ℃, the centrifugal 15min of 12000rpm collect supernatant.
The solubilization of inclusion bodies supernatant liquor is splined on the DEAE-52 anion-exchange column of handling well.Last sample finishes, with the abundant unconjugated albumen of flush away of 20mmol/L Tris.Cl/8 M urea (pH8.0), 0-0.3MNaCl gradient elution then, collect the solution of the corresponding collection tube of protein SDS-PAGE electrophoresis detection elution peak simultaneously, after the collection tube that contains target protein merges dialysis desalting, after the QFF anion column, 0-0.5M NaCl gradient elution, SDS-PAGE detects elution peak, contains the more and purer collection tube of target protein and merges, dialysis desalination renaturation.Renaturation process: damping fluid is 20mmol/L Tris.Cl/6M urea (pH8.0), 4 ℃ of dialysed overnight; Damping fluid is 20mmol/L Tris.Cl/3 M urea (pH8.0), 4 ℃ of dialysed overnight; Damping fluid be 20mmol/L Tris.Cl (pH8.0), 4 ℃ the dialysis 2 days.All contain the 5mM mercaptoethanol in all liquid.By preliminary reduction damping fluid urea concentration, thereby slowly remove the urea in the albumen and reach renaturation.
Whole purifying work is to finish on LKB chromatographic system instrument.
Purifying protein is through the SDS-polyacrylamide gel electrophoresis, and the gel densitometric scan shows this purity of protein near about 96%, and the HPLC purity testing shows that purity is also near 96%.
Mass spectrometric determination recombinant protein molecular weight shows that molecular weight of albumen of the present invention is 35.8KDa.
The analysis of N terminal amino acid sequence is finished by Peking University, and 15 amino acid of this protein N terminal are glycine (G)-Serine (S)-Methionin (K)-proline(Pro) (P)-proline(Pro) (P)-Serine (S)-glycine (G)-Serine (S)-proline(Pro) (P)-L-glutamic acid (E)-Threonine (T)-glycine (G)-L-Ala (A)-glycine (G)-L-Ala (A) successively.N end result proves that initial amino acid is correct, the coded amino acid coding triplet is correct.
Isoelectric point determination is 5.64.
Amino acid is formed and is conformed to peptide sequence.
Peptide quality fingerprinting atlas analysis shows that polypeptide Methionin of the present invention and arginine position in peptide sequence are accurately, thereby the indirect proof polypeptide structure is accurately.The methionine(Met) of this proteic codon ATG coding of encoding is not on the permanent staff in the albumen framework of sign indicating number.The proteic amino acid of the present invention is formed and is shown that this albumen is a kind of new Mycobacterium tuberculosis albumen.
Embodiment 3: Mycobacterium tuberculosis albumen of the present invention is used for the former cavy test of skin allergic reaction
Cavy DTH test: 100 300-350g cavys are divided into two groups at random, and 80 cavys are in the tubercule bacillus H37Rv of subcutaneous injection deactivation 0.2ml, and 4 weeks are carried out the DTH test in the injection back.Control group cavy injection 0.2ml physiological saline.All guinea pig back unhairings, in back, vertebra both sides corresponding site difference intradermal injection 0.1ml albumen of the present invention and 0.1ml PPD (requiring the injection site skin mound to occur is as the criterion), injected back 24 hours and detected in 48 hours the blush or horizontal, the vertical diameter (mm) of scleroma of injection site, horizontal, vertical mean diameter 〉=5mm is positive for injection site blush (or scleroma), mean diameter<5mm or reactionless (with 0 expression) are negative, the results are shown in Table 1.
Table 1 albumen of the present invention is used for the cavy DTH test-results of tubercule bacillus sensitization
Grouping | Reagent | The experimental guinea pig number of elements | Positive reaction number (%) | Average scleroma reaction (mm) |
Control group | The PPD contrast | ????20 | ????0(0) | |
Albumen of the present invention | ????20 | ????0(0) | ||
The sensitization group | The PPD contrast | ????80 | ????80 | ????9.95±1.5 |
Albumen of the present invention | ????80 | ????80 | ????9.23±1.9 |
The protein induced DTH of the present invention on average hardens and PPD ratio is 0.93, and the result shows that recombinant protein induces sensitized guinea pig to produce the DTH suitable with PPD and react.
The test of cavy DTH specificity: different mycobacterium sensitized guinea pigs, carry out the DTH test then.The result is as shown in table 2.
Table 2 Mycobacterium tuberculosis albumen of the present invention skin test allergen immunologic opsonin detected result
Allergen | Detection time (h) | The local blush of the cavy of different sensitinogen sensitization (scleroma) reaction | |||||||||
Tuberculosis | The Kansas | Bacille Calmette-Guerin vaccine | Accidental | Scrofula | |||||||
Number positive | Diameter (mm) * | Number positive | Diameter (mm) | Number positive | Diameter (mm) | Number positive | Diameter (mm) | Number positive | Diameter (mm) | ||
Human-like-PPD | ??24 | ????5/5 | ??/ | ????5/5 | ????/ | ????5/5 | ??/ | ????5/5 | ??/ | ????5/5 | ????/ |
??48 | ????5/5 | ??10.9/54.5 | ????5/5 | ????9.0/45.0 | ????5/5 | ??8.6/43.0 | ????4/5 | ??6.1/30.5 | ????5/5 | ????9.2/46.0 | |
Albumen of the present invention | ??24 | ????5/5 | ??/ | ????2/5 | ????/ | ????3/5 | ??/ | ????0/5 | ??/ | ????1/5 | ????/ |
??48 | ????5/5 | ??10.7/53.5 | ????0/5 | ????0 | ????2/5 | ??2.4/12.0 | ????0/5 | ??0 | ????1/5 | ????1.3/6.5 |
Annotate: diameter: mean value/accumulated value; /: do not detect
Table 2 result shows that albumen of the present invention and human-like PPD and Mycobacterium tuberculosis sensitized guinea pig all are positive, and albumen of the present invention and mycobacterium kansasii and accidental mycobacterium sensitized guinea pig no cross reaction, is lower than human-like PPD with bacille Calmette-Guerin vaccine sensitized guinea pig and scrofula mycobacterium sensitized guinea pig positive reaction rate.
More than test shows that the recombinant protein of the present invention of escherichia coli expression has the good allergen property renderd a service, and the DTH reaction of inducing the mycobacterium tuberculosis sensitized guinea pig to produce is suitable with PPD, but specificity is far above PPD.
Embodiment 4: Mycobacterium tuberculosis albumen of the present invention is used for the former clinical trial of skin allergic reaction
Clinical trial: selected lunger is essential through clinical definite.Consubstantiality both arms Motouw method, the 1ml disposable syringe of promptly sterilizing is drawn 0.1ml PPD in the 1/3 place intradermal injection of right forearm palmar, and seeing has skin mound proof to inject successfully.Other gets the 1ml disposable syringe, draws 0.1ml albumen of the present invention in the 1/3 place intradermal injection of left forearm palmar, and seeing has skin mound proof to inject successfully.In injection back 24 hours and 48 hours double blinding sentence read result, horizontal, vertical mean diameter 〉=5mm is positive for injection site blush (or scleroma), and mean diameter<5mm or reactionless (with 0 expression) are negative.510 routine pulmonary tuberculosis patient tuerculoderma results are as shown in table 3.
Table 3 pulmonary tuberculosis patient skin test reactions result
Observing time (hour) | Positive reaction rate (%) | Reaction is footpath (mm) X ± SD all | Positive reaction is footpath (mm) X ± SD all | Untoward reaction (%) | |
Albumen of the present invention | ????24 | ?73.3(374/510) | ??7.31±4.58 | ????9.63±2.94 | ????0 |
????48 | ?68.2(347/510) | ??5.24±4.06 | ????7.64±2.42 | ????0 | |
????PPD | ????24 | ?76.3(389/510) | ??8.16±5.59 | ????10.66±3.79 | ????0.2(1/510) |
????48 | ?78.2(399/510) | ??9.74±6.23 | ????12.40±4.09 | ????5.9(30/510) |
Table 3 shows that albumen tuerculoderma result of the present invention observed with 24-48 hour, 24 hours albumen tuerculoderma positive reaction rates of the present invention and 48 hours suitable (X of PPD tuerculoderma positive reaction rate
2=3.07, P>0.05).
It is suitable with PPD that above-mentioned evidence, albumen of the present invention are used for tuberculosis skin test diagnostic reaction positive rate, can meet clinical needs, and do not see any side reaction.On the contrary, detect with PPD, bubble or lymphangitis appear in 5.9% pulmonary tuberculosis patient PPD tuerculoderma.
Embodiment 5: Mycobacterium tuberculosis albumen of the present invention is used for serum diagnosis
The ELISA method detects 291 parts of serum: the every hole of albumen of the present invention bag is by 0.2-1 μ g, and PPD wraps by 0.2-1 μ g, and control wells adds coating buffer.This tests used coating buffer is 2.94g/L NaHCO
3With 1.50g/L Na
2CO3.Bag is discarded liquid by more than 2 hours, washes plate 3 times with PBST then, each 3 minutes.Sample diluting liquid (PBST that contains 0.1%BSA) 1: 100 dilution serum sample to be checked, every hole adds 100 μ l, 37 ℃ 1 hour, ditto wash plate 3 times.Dilute two anti-rabbit anti-human iggs of HRP mark on request with sample diluting liquid (PBST that contains 0.1%BSA), every hole adds 100 μ l, 37 ℃ 1 hour, ditto wash plate 3 times, every hole adds 100 μ 1 colour developing liquid, and (citric acid and biphosphate are received damping fluid dissolving DAB, face with before adding H
2O
2) colour developing, add 2 termination reactions of 2M sulfuric acid, measure each OD of 490nm wavelength place, hole on the microplate reader.Positive greater than 2 times of contrast OD values.29l part serum ELISA detected result sees Table 4.
Table 4 recombinant protein detects the result of serum with the ELISA method
The serum source | Umber | Susceptibility (%) | Specificity (%) | ||
??TB-PPD | Albumen of the present invention | ??TB-PPD | Albumen of the present invention | ||
Pulmonary tuberculosis patient | |||||
The smear feminine gender | ??78 | ??54(69.2) | ??52(66.7) | ??--- | ??--- |
The smear positive | ????30 | ????30(100.0) | ????29(96.7) | ????--- | ????--- |
The healthy blood donor | ????105 | ????6(5.7) | ????3(2.9) | ????94.3 | ????97.1 |
BCG (Bacille Calmette-Guerin) vaccination | |||||
Sun commentaries on classics person | ????78 | ????26(32.1) | ????11(14.0) | ????67.9 | ????86.0 |
To show that albumen of the present invention is used for the serum of tuberculosis patients detection sensitivity suitable with PPD for the result in the table, but specificity is higher than PPD, influenced by the BCG inoculation and be starkly lower than PPD, this country to BCG plan inoculation adopts tuberculosis serological diagnosis significant.
Embodiment 5: Mycobacterium tuberculosis albumen of the present invention is used for the cerebrospinal fluid diagnosis
Spot enzyme immunity percolation method (DIEFA) rapid detection CSF antibody: get suitable concn the dry rear enclosed of albumen 0.1ml point film of the present invention, film, add CSF, wash film, add ELIAS secondary antibody, wash film, colour developing.Occur the black colorant spot on every film and be judged to the positive.Entire operation was finished in 15 minutes.130 parts of cerebrospinal fluid samples detect with DIEFA, the results are shown in Table 5.
Table 5 Mycobacterium tuberculosis albumen of the present invention is used for the result of cerebrospinal fluid diagnosis
Number of samples | The sample type | Enzyme mark percolation process detects IgG antibody | ||
Positive anti-property number | The positive reaction rate | Specificity | ||
100 parts | Tuberculosis patient cerebrospinal fluid | ????55 | ????55% | |
32 parts | Non-tuberculosis patient cerebrospinal fluid | ????1 | ??97% |
Table 5 shows that albumen tuberculosis patient cerebrospinal fluid of the present invention detects positive rate and reaches 55%, and specificity reaches 97%.Set up the tuberculosis antibody in the rapid detection cerebrospinal fluid, can be the tuberculous meningitis quick diagnosis supplementary means is provided.
It is higher that table 4 and 5 results show that recombinant protein is used for antibody test susceptibility, and have higher specificity.
Sequence table
<110〉village, beautiful brightness
What, elegant cloud
Open, little firm
<120〉be used for the Mycobacterium tuberculosis albumen of diagnosis of tuberculosis
<130>PLMD4562N
<160>5
<170>PatentIn?version?3.1
<210>1
<211>1125
<212>DNA
<213〉Mycobacterium tuberculosis H37Rv (Mycobacterium tuberculosis H37Rv)
<400>1
gtgaaaattc?gtttgcatac?gctgttggcc?gtgttgaccg?ctgcgccgct?gctgctagca??????60
gcggcgggct?gtggctcgaa?accaccgagc?ggttcgcctg?aaacgggcgc?cggcgccggt?????120
actgtcgcga?ctacccccgc?gtcgtcgccg?gtgacgttgg?cggagaccgg?tagcacgctg?????180
ctctacccgc?tgttcaacct?gtggggtccg?gcctttcacg?agaggtatcc?gaacgtcacg?????240
atcaccgctc?agggcaccgg?ttctggtgcc?gggatcgcgc?aggccgccgc?cgggacggtc?????300
aacattgggg?cctccgacgc?ctatctgtcg?gaaggtgata?tggccgcgca?caaggggctg?????360
atgaacatcg?cgctagccat?ctccgctcag?caggtcaact?acaacctgcc?cggagtgagc?????420
gagcacctca?agctgaacgg?aaaagtcctg?gcggccatgt?accagggcac?catcaaaacc?????480
tgggacgacc?cgcagatcgc?tgcgctcaac?cccggcgtga?acctgcccgg?caccgcggta?????540
gttccgctgc?accgctccga?cgggtccggt?gacaccttct?tgttcaccca?gtacctgtcc?????600
aagcaagatc?ccgagggctg?gggcaagtcg?cccggcttcg?gcaccaccgt?cgacttcccg????660
gcggtgccgg?gtgcgctggg?tgagaacggc?aacggcggca?tggtgaccgg?ttgcgccgag????720
acaccgggct?gcgtggccta?tatcggcatc?agcttcctcg?accaggccag?tcaacgggga????780
ctcggcgagg?cccaactagg?caatagctct?ggcaatttct?tgttgcccga?cgcgcaaagc????840
attcaggccg?cggcggctgg?cttcgcatcg?aaaaccccgg?cgaaccaggc?gatttcgatg????900
atcgacgggc?ccgccccgga?cggctacccg?atcatcaact?acgagtacgc?catcgtcaac????960
aaccggcaaa?aggacgccgc?caccgcgcag?accttgcagg?catttctgca?ctgggcgatc???1020
accgacggca?acaaggcctc?gttcctcgac?caggttcatt?tccagccgct?gccgcccgcg???1080
gtggtgaagt?tgtctgacgc?gttgatcgcg?acgatttcca?gctag???????????????????1125
<210>2
<211>1056
<212>DNA
<213〉artificial sequence
<220>
<223〉to the description of artificial sequence: the sudden change of sequence 1
<400>2
atgggctcta?aaccaccgag?cggttcgcct?gaaacgggcg?ccggcgccgg?tactgtcgcg?????60
actacccccg?cgtcgtcgcc?ggtgacgttg?gcggagaccg?gtagcacgct?gctctacccg????120
ctgttcaacc?tgtggggtcc?ggcctttcac?gagaggtatc?cgaacgtcac?gatcaccgct????180
cagggcaccg?gttctggtgc?cgggatcgcg?caggccgccg?ccgggacggt?caacattggg????240
gcctccgacg?cctatctgtc?ggaaggtgat?atggccgcgc?acaaggggct?gatgaacatc????300
gcgctagcca?tctccgctca?gcaggtcaac?tacaacctgc?ccggagtgag?cgagcacctc????360
aagctgaacg?gaaaagtcct?ggcggccatg?taccagggca?ccatcaaaac?ctgggacgac????420
ccgcagatcg?ctgcgctcaa?ccccggcgtg?aacctgcccg?gcaccgcggt?agttccgctg????480
caccgctccg?acgggtccgg?tgacaccttc?ttgttcaccc?agtacctgtc?caagcaagat????540
cccgagggct?ggggcaagtc?gcccggcttc?ggcaccaccg?tcgacttccc?ggcggtgccg????600
ggtgcgctgg?gtgagaacgg?caacggcggc?atggtgaccg?gttgcgccga?gacaccgggc????660
tgcgtggcct?atatcggcat?cagcttcctc?gaccaggcca?gtcaacgggg?actcggcgag????720
gcccaactag?gcaatagctc?tggcaatttc?ttgttgcccg?acgcgcaaag?cattcaggcc????780
gcggcggctg?gcttcgcatc?gaaaaccccg?gcgaaccagg?cgatttcgat?gatcgacggg????840
ccggccccgg?acggctaccc?gatcatcaac?tacgagtacg?ccatcgtcaa?caaccggcaa????900
aaggacgccg?ccaccgcgca?gaccttgcag?gcatttctgc?actgggcgat?caccgacggc????960
aacaaggcct?cgttcctcga?ccaggttcat?ttccagccgc?tgccgcccgc?ggtggtgaag???1020
ttgtctgacg?cgttgatcgc?gacgatttcc?agctaa?????????????????????????????1056
<210>3
<211>350
<212>PRT
<213〉artificial sequence
<220>
<223〉to the description of artificial sequence: reorganization
<400>3
Gly?Ser?Lys?Pro?Pro?Ser?Gly?Ser?Pro?Glu?Thr?Gly?Ala?Gly?Ala?Gly
1???????????????5???????????????????10??????????????????15
Thr?Val?Ala?Thr?Thr?Pro?Ala?Ser?Ser?Pro?Val?Thr?Leu?Ala?Glu?Thr
20??????????????????25??????????????????30
Gly?Ser?Thr?Leu?Leu?Tyr?Pro?Leu?Phe?Asn?Leu?Trp?Gly?Pro?Ala?Phe
35??????????????????40??????????????????45
His?Glu?Arg?Tyr?Pro?Asn?Val?Thr?Ile?Thr?Ala?Gln?Gly?Thr?Gly?Ser
50??????????????????55??????????????????60
Gly?Ala?Gly?Ile?Ala?Gln?Ala?Ala?Ala?Gly?Thr?Val?Asn?Ile?Gly?Ala
65??????????????????70??????????????????75??????????????????80
Ser?Asp?Ala?Tyr?Leu?Ser?Glu?Gly?Asp?Met?Ala?Ala?His?Lys?Gly?Leu
85??????????????????90??????????????????95
Met?Asn?Ile?Ala?Leu?Ala?Ile?Ser?Ala?Gln?Gln?Val?Asn?Tyr?Asn?Leu
100?????????????????105?????????????????110
Pro?Gly?Val?Ser?Glu?His?Leu?Lys?Leu?Asn?Gly?Lys?Val?Leu?Ala?Ala
115?????????????????120?????????????????125
Met?Tyr?Gln?Gly?Thr?Ile?Lys?Thr?Trp?Asp?Asp?Pro?Gln?Ile?Ala?Ala
130?????????????????135?????????????????140
Leu?Asn?Pro?Gly?Val?Asn?Leu?Pro?Gly?Thr?Ala?Val?Val?Pro?Leu?His
145?????????????????150?????????????????155?????????????????160
Arg?Ser?Asp?Gly?Ser?Gly?Asp?Thr?Phe?Leu?Phe?Thr?Gln?Tyr?Leu?Ser
165?????????????????170?????????????????175
Lys?Gln?Asp?Pro?Glu?Gly?Trp?Gly?Lys?Ser?Pro?Gly?Phe?Gly?Thr?Thr
180?????????????????185?????????????????190
Val?Asp?Phe?Pro?Ala?Val?Pro?Gly?Ala?Leu?Gly?Glu?Asn?Gly?Asn?Gly
195?????????????????200?????????????????205
Gly?Met?Val?Thr?Gly?Cys?Ala?Glu?Thr?Pro?Gly?Cys?Val?Ala?Tyr?Ile
210?????????????????215?????????????????220
Gly?Ile?Ser?Phe?Leu?Asp?Gln?Ala?Ser?Gln?Arg?Gly?Leu?Gly?Glu?Ala
225?????????????????230?????????????????235?????????????????240
Gln?Leu?Gly?Asn?Ser?Ser?Gly?Asn?Phe?Leu?Leu?Pro?Asp?Ala?Gln?Ser
245?????????????????250?????????????????255
Ile?Gln?Ala?Ala?Ala?Ala?Gly?Phe?Ala?Ser?Lys?Thr?Pro?Ala?Asn?Gln
260?????????????????265?????????????????270
Ala?Ile?Ser?Met?Ile?Asp?Gly?Pro?Ala?Pro?Asp?Gly?Tyr?Pro?Ile?Ile
275?????????????????280?????????????????285
Asn?Tyr?Glu?Tyr?Ala?Ile?Val?Asn?Asn?Arg?Gln?Lys?Asp?Ala?Ala?Thr
290?????????????????295?????????????????300
Ala?Gln?Thr?Leu?Gln?Ala?Phe?Leu?His?Trp?Ala?Ile?Thr?Asp?Gly?Asn
305?????????????????310?????????????????315?????????????????320
Lys?Ala?Ser?Phe?Leu?Asp?Gln?Val?His?Phe?Gln?Pro?Leu?Pro?Pro?Ala
325?????????????????330?????????????????335
Val?Val?Lys?Leu?Ser?Asp?Ala?Leu?Ile?Ala?Thr?Ile?Ser?Ser
340?????????????????345?????????????????350
<210>4
<211>18
<212>DNA
<213〉artificial sequence
<220>
<223〉to the description of artificial sequence: upstream primer
<400>4
cgcatgccat?gggctctaaa?ccaccgagcg?gttcgcc???????????????????????????????37
18
<210>5
<211>20
<212>DNA
<213〉artificial sequence
<220>
<223〉to the description of artificial sequence: downstream primer
<400>5
cgggatccaa?tgctggaaat?cgtcgcgatc?aacg??????????????????????????????????34
Claims (10)
1. nucleic acid, it has the nucleotide sequence shown in sequence 2.
2. proteic genetically engineered recombination and preparation of Mycobacterium tuberculosis, it is characterized in that application rights requires 1 nucleic acid construct expression vector, and in the prokaryotic host cell that this carrier was fit to, express the Mycobacterium tuberculosis albumen of the described nucleic acid encoding of claim 1.
3. the method for claim 2, wherein said expression vector is PET9d, PET22b (+) or PET15b plasmid.
4. the method for claim 2, wherein said host cell is e. coli bl21 (DE3) or HMS174 (DE3).
5. according to the Mycobacterium tuberculosis albumen of each described method preparation in the claim 2 to 4.
6. the proteic composition of Mycobacterium tuberculosis that comprises claim 5.
7. the described composition of claim 6, it is a diagnostic reagent of tuberculosis.
8. the described composition of claim 6, it is a tuberculosis epidemiology investigation and monitoring reagent.
9. the proteic test kit of Mycobacterium tuberculosis that comprises claim 5.
10. the test kit of claim 9, it is diagnosis of tuberculosis and tuberculosis epidemiology investigation and monitoring test kit.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410044568XA CN100393876C (en) | 2004-05-11 | 2004-05-11 | Protein of tuberculosis in use for diagnosing tuberculosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410044568XA CN100393876C (en) | 2004-05-11 | 2004-05-11 | Protein of tuberculosis in use for diagnosing tuberculosis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1696289A true CN1696289A (en) | 2005-11-16 |
CN100393876C CN100393876C (en) | 2008-06-11 |
Family
ID=35349182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200410044568XA Expired - Lifetime CN100393876C (en) | 2004-05-11 | 2004-05-11 | Protein of tuberculosis in use for diagnosing tuberculosis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100393876C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102713629A (en) * | 2009-11-20 | 2012-10-03 | 俄勒冈健康科学大学 | Methods for detecting a mycobacterium tuberculosis infection |
CN105181837A (en) * | 2015-08-28 | 2015-12-23 | 程永娟 | Mycobacterium tuberculosis detection method |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714593A (en) * | 1995-02-01 | 1998-02-03 | Institut Pasteur | DNA from mycobacterium tuberculosis which codes for a 45/47 kilodalton protein |
AU2003224313A1 (en) * | 2002-04-27 | 2003-11-17 | The Secretary Of State For Environment, Food And Rural Affairs | Mycobacterial antigens and uses thereof |
-
2004
- 2004-05-11 CN CNB200410044568XA patent/CN100393876C/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102713629A (en) * | 2009-11-20 | 2012-10-03 | 俄勒冈健康科学大学 | Methods for detecting a mycobacterium tuberculosis infection |
CN105181837A (en) * | 2015-08-28 | 2015-12-23 | 程永娟 | Mycobacterium tuberculosis detection method |
Also Published As
Publication number | Publication date |
---|---|
CN100393876C (en) | 2008-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101624422B (en) | Schistosoma japonicum recombinant multi-epitope antigens, method for expressing and purifying same and application thereof | |
CN1068266A (en) | Human immunodeficiency virus's vaccine and Therapeutic Method thereof | |
CN1810838A (en) | Recombinant antigen protein for diagnosing ox tuberculosis and its prepn process | |
CN1858062A (en) | Enzyme-linked immunosorbent test detecting reagent kit for non-structure protein of pig and cow foot and mouth disease virus | |
CN1148449C (en) | Mutants of streptococcal toxin C and methods of use | |
CN1899609A (en) | Pneumococcus polysaccharide protein coupling vaccine and its preparing method | |
CN101921325A (en) | Antigen capable of increasing CD4 + CD25 + Foxp3 + regulatory T cells and application thereof | |
CN1694725A (en) | Early detection of mycobacterial disease using peptides | |
CN101074442A (en) | Recombinant expression and use for pertussis vaccine protective antigen | |
CN1916633A (en) | Method and kit for detecting treponema pallidum | |
CN1769294A (en) | Recombinant akabane virus capsid protein, its preparation method and uses | |
CN1696289A (en) | Protein of tuberculosis in use for diagnosing tuberculosis | |
CN1884302A (en) | Staphylococcus aureus fusion protein of fibronectin and bindin, its preparation method and uses | |
CN1928562A (en) | Enzyme linked immunoreaction reagent kit for detecting rabies virus | |
CN1800398A (en) | Prunus necrotic ring spot virus coat protein gene and its special primer for checking | |
CN1657617A (en) | Clone, expression and anti-tick immanoprotection action of falcate rhipicephalus RhcA and RhcB genes | |
CN1216074C (en) | Mimic peptide of schistosoma japonice ovum antigen and its screening and application | |
CN1185254C (en) | First hypervariable region antigen of hepatitis C and fusion antigen | |
CN1847397A (en) | EHEC 0157 shiga-like toxin IIA resisting subunit monoclonal antibody 5F3 light and heavy chain variable region gene and its application | |
CN101063143A (en) | Recombined cytomegalovirus gp52 protein and its application | |
CN1300318C (en) | DNA which code Mycoplasma mycoides subspecies N terminal lipoprotein | |
CN110028590B (en) | pCzn1-gC fusion protein and application thereof | |
CN1616485A (en) | SARS coronavirus structure protein ORF3 and its use | |
CN1592633A (en) | T-cell epitodes in carboxypeptidase G2 | |
CN1884549A (en) | SjADA coding gene, its construction method and its in vitro fusion expression product and expression method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: GUANGDONG HANDSOME BIO-PHARMACEUTICAL CO.,LTD. Assignor: THE 309 HOSPITAL OF PLA Contract record no.: 2011990000438 Denomination of invention: Protein of tuberculosis in use for diagnosing tuberculosis Granted publication date: 20080611 License type: Exclusive License Open date: 20051116 Record date: 20110608 |
|
CX01 | Expiry of patent term |
Granted publication date: 20080611 |
|
CX01 | Expiry of patent term |